GEHC GE HealthCare Technologies Inc

$GEHC Just sitting here accumulating. It isn't sexy, but in the end, it will pay off in 2027.

$GEHC GE Healthcare is setting up to be a powerhouse once the market shifts towards this market. I see it happening in 2027. Buy and hold. Plus, what they do is needed. As a person who does a lot of work with cancer patients, you see the need for what GE is doing. The PET acquisition is perfect for the long-term. Like I said, this sector is not sexy but it will be a winner.

GE HealthCare To Acquire SOFIE Biosciences For $945M — Here’s What GEHC Investors Need To Know $GEHC https://stocktwits.com/news/equity/markets/ge-health-care-to-acquire-sofie-biosciences-for-945-m-here-s-what-gehc-investors-need-to-know/cZDp6hGRBjB

$GEHC | GE HealthCare Q3 2026 Earnings - Q3 Adj EPS: $1.34 (est $1.21) - Q3 Adj EBIT: $913M (est $835.9M) - Q3 Rev: $5.5B (est $5.35B) - Sees FY Adj EBIT Margin: 15.5% To 15.7% (saw 15.4% To 15.7%) - Sees FY Adj EPS: $4.95 To $5.05 (saw $4.80 To $5)

$GEHC GE HealthCare is acquiring Sofie Biosciences, a PET radiotracer manufacturer, for 945M in cash. Close expected in the first half of 2027. What is actually being bought is a logistics network: 15 US contract-manufacturing sites and 21 cyclotrons. F18 tracers carry a half-life of about 110 minutes, so production has to sit close to the scanner. Sofie keeps its existing customers after closing, including other radiopharma companies. GEHC also gets US rights to FAPI-74, a Phase III PET tracer with pan-cancer potential; it already holds rights outside the US. GEHC expects the deal accretive to revenue growth, adjusted EBIT margin, and adjusted EPS in the first full year.

$GEHC https://www.cnbc.com/2026/10/28/stocks-making-the-biggest-moves-midday-wen-wing-ffiv-enph-lh.html GE HealthCare Technologies — Shares gained 8% after GE HealthCare Technologies lifted its full-year guidance. The company anticipates adjusted earnings will range from $4.95 to $5.05 per share, and it sees organic revenue growth of roughly 4% year over year.

$GEHC reported earnings before the open today. EPS beat estimates: $1.34 vs. $1.20 expected, according to Stock Meadow. What do you think?

$GEHC this makes the pain from my solar, telecom, and Boeing wreckage about 1% more tolerable.

$GEHC Q3 adjusted EPS was 1.34 dollars vs 1.21 dollars expected, on revenue of 5.51 billion dollars, up 7.2%. Adjusted EBIT margin was 16.6%, up 180 basis points year over year. That margin line was the worry coming in. Q2 margin was 14.2% with inflation running as a headwind, and the full year expansion target was only 10 to 40 basis points. Orders went the other way though. Organic orders grew 4.0%, book-to-bill was 1.03x, down from a record 1.15x in Q2, and backlog eased to 23.7 billion dollars from 23.9 billion. Full year adjusted EPS guidance still went up, to 4.95 to 5.05 dollars from 4.80 to 5.00 dollars.

$GEHC Can GE HealthCare keep Q3's 25.1% adjusted EPS growth when its raised 2026 guide implies a slower Q4? 🚀 GE HealthCare, the medical imaging, diagnostics and patient care company worth about $32.35B at $71.11 a share at 16:00 ET on October 27, 2026, raised its 2026 adjusted EPS guide to $4.95–$5.05 from $4.80–$5.00 with its Q3 results ⚠️ Taking the $3.46 earned in the first nine months out of the new range leaves Q4 adjusted EPS of $1.49–$1.59, only 3.5%–10.4% above the roughly $1.44 implied for Q4 2025, so the guide assumes growth well below Q3's pace 📈 In favor of the bulls, organic orders grew 4.0% with a book-to-bill of 1.03 and a $23.7B backlog, the free cash flow guide went to $1.6B+ from about $1.6B, and $71.11 is about 14 times the midpoint of the new EPS range 📅 Next: Earnings call October 28, 2026 at 8:30 am ET; Patient Care Solutions head Jeannette Bankes leaves November 15, 2026 Source: SEC 8-K Q3 release, Oct 28

$GEHC reports earnings tomorrow before the open. I’m bullish heading into the report: GEHC has beaten EPS estimates in 7 of its last 8 reports, according to Stock Meadow. Analysts expect EPS of $1.20. What are you watching for?

$GEHC reports Wednesday before the open. Zacks consensus is 1.21 dollars a share, up 13.1% from a year ago, on revenue of 5.36 billion dollars, up just 4.2%. Q2 orders were the strongest since the 2023 spin, organic orders up 11.1%, book-to-bill a record 1.15x, backlog a record 23.9 billion dollars. A lot of that is longer-cycle radiology though, which management says contributes more in 2027. Margin is probably the tighter test. Q2 adjusted EBIT margin fell 40 basis points to 14.2% with inflation running about 120 basis points of headwind, and the full-year expansion target is only 10 to 40 basis points.

$GEHC ex-dividend date for GE HealthCare Technologies Inc. (GEHC) is tomorrow. Today is the last day. Ex-Dividend Date: The cutoff day; buying on or after this date means no dividend.